Compare XYF & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | XYF | ENGN |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.6M | 605.5M |
| IPO Year | 2018 | N/A |
| Metric | XYF | ENGN |
|---|---|---|
| Price | $5.75 | $8.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 215.6K | ★ 239.9K |
| Earning Date | 11-20-2025 | 12-22-2025 |
| Dividend Yield | ★ 9.70% | N/A |
| EPS Growth | ★ 49.84 | N/A |
| EPS | ★ 5.72 | N/A |
| Revenue | ★ $1,106,908,607.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.01 | ★ N/A |
| Revenue Growth | ★ 47.14 | N/A |
| 52 Week Low | $5.44 | $2.65 |
| 52 Week High | $20.36 | $11.14 |
| Indicator | XYF | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 26.32 | 53.48 |
| Support Level | $5.60 | $7.57 |
| Resistance Level | $6.04 | $9.81 |
| Average True Range (ATR) | 0.35 | 0.68 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 16.85 | 46.64 |
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.